Wegovy 7.2mg (Wegovy HD): What the High Dose Means

Wegovy 7.2mg, sold as Wegovy HD, is the high-dose version of Wegovy: a once-weekly 7.2 mg semaglutide injection pen, approved by the US FDA on March 19, 2026, for long-term weight reduction in adults with obesity, or overweight plus at least one weight-related condition. Under the label it is an extra step for some adults already tolerating the 2.4 mg dose, not a starting dose. The exact label, not an online thread, decides who it's for and how it's used.

Who it's meant for

Under the US label, the usual Wegovy maintenance dose for adults is still 2.4 mg (or 1.7 mg). The 7.2 mg dose is an option for adults who have tolerated 2.4 mg for at least 4 weeks when their clinician thinks more weight reduction is needed. It isn't a starting dose, and its safety hasn't been established in teens or for the MASH (fatty liver) indication. Approval and availability outside the US may differ.

What a high dose does, and doesn't, mean

A high dose like 7.2mg Wegovy is not a shortcut to try on your own. Prescription medicines are stepped up and maintained according to product-specific instructions meant to balance benefit and safety. Never split, combine or improvise doses with pens or vials to make up a different strength; that can lead to serious medication errors and side effects.

What the trials found

The label describes two 72-week randomized trials comparing 7.2 mg, 2.4 mg and placebo:

• Adults with obesity, without diabetes (1,407 people): average weight change was −18.8% on 7.2 mg, −15.5% on 2.4 mg and −3.9% on placebo. That's about 3.3 percentage points more than 2.4 mg.
• Adults with obesity and type 2 diabetes (512 people): −13.2% on 7.2 mg, −10.4% on 2.4 mg and −3.8% on placebo. The FDA noted blood-sugar control (HbA1c) was similar to the lower dose.

These are group averages from company-run trials. Individual results vary, and comparing them with numbers from other medicines' trials isn't the same as a head-to-head study.

What about tolerability?

The higher dose comes with some trade-offs worth knowing:

• Altered skin sensations. Tingling, burning, skin sensitivity or pain (called dysesthesia) was reported by 22% of people on 7.2 mg, compared with 6% on 2.4 mg and 0.3% on placebo. About a quarter of those affected had their dose lowered and a few paused or stopped; most of them recovered, and symptoms tended to clear faster when the dose was adjusted. The FDA said it's continuing to look into this reaction.
• Hair loss was reported in 5.8% on 7.2 mg, 3.3% on 2.4 mg and 1.0% on placebo, more often in women. Our guide to hair loss and muscle loss on GLP-1s explains what's known.
• Digestive side effects like nausea, vomiting, diarrhea, constipation and stomach pain remain the most common. About 5% of people on either 7.2 mg or 2.4 mg stopped treatment because of side effects, compared with 2% on placebo.

The full prescribing information also covers the boxed thyroid warning and other precautions such as pancreatitis and gallbladder problems. If you notice new skin sensations or digestive symptoms, tell your prescriber rather than changing the dose yourself.

What should someone ask?

Is this dose approved and available where I live? Does the evidence fit my situation? How will we track response and side effects? What are the alternatives? And try not to judge your own progress against someone else's; a slower result isn't a reason to change a dose on your own.

Wegovy HD is a development worth following, but a high-dose headline shouldn't turn into an unsupervised dosing plan. For how it fits with the other 2026 options, see the new weight-loss medicines of 2026.

Common questions

What is Wegovy high dose (Wegovy HD)?

Wegovy HD is the brand name for the 7.2 mg once-weekly semaglutide dose of Wegovy. The US FDA approved it on March 19, 2026, for long-term weight reduction in adults with obesity, or overweight plus at least one weight-related condition. Approval and availability outside the US may differ.

Is the Wegovy 7.2mg pen a starting dose?

No. Under the US label, the usual maintenance dose for adults is still 2.4 mg (or 1.7 mg). The 7.2 mg dose is an option only for adults who have tolerated 2.4 mg for at least 4 weeks when their clinician thinks more weight reduction is needed, and its safety hasn't been established in teens.

How much more weight did people lose on 7.2 mg than on 2.4 mg?

In the 72-week trial of adults with obesity but without diabetes, average weight change was −18.8% on 7.2 mg versus −15.5% on 2.4 mg, about 3.3 percentage points more. In adults with obesity and type 2 diabetes it was −13.2% versus −10.4%. These are group averages from company-run trials, and individual results vary.

What side effects are more common on the high dose?

Altered skin sensations (tingling, burning, sensitivity or pain) were reported by 22% of people on 7.2 mg, compared with 6% on 2.4 mg. Hair loss was reported in 5.8% versus 3.3%. Digestive side effects like nausea, vomiting, diarrhea and constipation remain the most common at both doses, and about 5% of people on either dose stopped because of side effects.

Can I make 7.2 mg by combining two Wegovy pens?

No. Never split, combine or improvise doses with pens or vials to make up a different strength; that can lead to serious medication errors and side effects. If you think a different dose might fit your situation, that is a conversation for your prescriber, not something to work out at home.